PCRX Stock-Based Compensation
Pacira Biosciences Inc · Stock-Based Compensation
PCRX Stock-Based Compensation
Latest reported$55.97Mperiod ending
PCRX TTM Stock-Based Comp ($23.00K → $55.97M)
TTM stock-based compensation
High-resolution chart · PNG
PCRX stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 55,974,000 | |
| 56,488,000 | |
| 57,502,000 | |
| 56,269,000 | |
| 55,521,000 | |
| 52,573,000 | |
| 51,171,000 | |
| 51,325,000 | |
| 50,625,000 | |
| 49,056,000 | |
| 47,895,000 | |
| 48,152,000 | |
| 48,304,000 | |
| 48,893,000 | |
| 48,092,000 | |
| 35,415,000 | |
| 33,518,000 | |
| 32,435,000 | |
| 31,356,000 | |
| 42,252,000 | |
| 42,421,000 | |
| 41,183,000 | |
| 31,073,000 | |
| 29,366,000 | |
| 27,656,000 | |
| 26,216,000 | |
| 33,650,000 | |
| 32,647,000 | |
| 31,510,000 | |
| 30,774,000 | |
| 31,725,000 | |
| 31,733,000 | |
| 32,289,000 | |
| 32,586,000 | |
| 31,601,000 | |
| 31,139,000 | |
| 29,837,000 | |
| 30,158,000 | |
| 31,248,000 | |
| 33,244,000 | |
| 34,710,000 | |
| 34,341,000 | |
| 33,368,000 | |
| 31,263,000 | |
| 30,123,000 | |
| 28,364,000 | |
| 24,822,000 | |
| 20,485,000 | |
| 16,575,000 | |
| 13,263,000 | |
| 11,513,000 | |
| 9,783,000 | |
| 7,475,000 | |
| 6,289,000 | |
| 4,776,000 | |
| 3,748,000 | |
| 2,721,000 | |
| 2,233,000 | |
| 2,493,000 | |
| 1,971,000 | |
| 1,535,000 | |
| 990,000 | |
| 23,000 | |
| 23,000 | |
| 22,000 |